<DOC>
	<DOCNO>NCT02500407</DOCNO>
	<brief_summary>This study design evaluate safety pharmacokinetics BTCT4465A administer single agent intravenous ( IV ) infusion participant relapse refractory B-cell NHL CLL . The study consist dose-escalation stage expansion stage participant enrol indication-specific cohort .</brief_summary>
	<brief_title>A Safety Pharmacokinetic Study BTCT4465A , With Without Single-dose Obinutuzumab Pretreatment , Non-Hodgkin 's Lymphoma ( NHL ) Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Doseescalation stage : Grade 1 3b follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , transform FL , Richter 's transformation , diffuse large Bcell lymphoma ( DLBCL ) , primary mediastinal Bcell lymphoma ( PMBCL ) , small lymphocytic lymphoma ( SLL ) , mantle cell lymphoma ( MCL ) , CLL Doseexpansion stage : DLBCL , transform FL , Grade 1 3a FL , MZL , CLL Adverse event prior anticancer therapy resolve Grade 1 good Adequate hepatic , hematologic , renal function For participant partner childbearing potential , agreement remain abstinent utilize effective contraception Pregnant lactate woman Monoclonal antibody , radioimmunoconjugate , antibodydrug conjugate , radiotherapy , chemotherapy , investigational anticancer agent within 4 week prior study drug Systemic immunotherapy within 12 week 5 halflives drug prior study drug Systemic immunosuppressive medication within 2 week prior study drug Autologous stem cell transplantation ( SCT ) within 100 day prior study drug , prior allogeneic SCT solid organ transplantation Autoimmune disease exception controlled/treated hypothyroidism , diseaserelated immune thrombocytopenic purpura , hemolytic anemia History confirm progressive multifocal leukoencephalopathy ( PML ) History central nervous system ( CNS ) lymphoma CNS disease Significant cardiovascular pulmonary disease Current infection , prior infection require IV antibiotic and/or hospitalization within 4 week prior study drug Major surgery within 4 week prior study drug Hepatitis B C human immunodeficiency virus ( HIV ) Receipt live attenuate vaccine within 4 week prior study drug History drug alcohol abuse within 12 week prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>